Invention Grant
- Patent Title: Amide prodrug of gemcitabine, compositions and use thereof
- Patent Title (中): 吉西他滨的前药药物，组合物及其用途
-
Application No.: US11719705Application Date: 2005-11-30
-
Publication No.: US07691827B2Publication Date: 2010-04-06
- Inventor: David Michael Bender , David Michael Remick
- Applicant: David Michael Bender , David Michael Remick
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Elizabeth A. McGraw; Arleen Palmberg
- International Application: PCT/US2005/043125 WO 20051130
- International Announcement: WO2006/065525 WO 20060622
- Main IPC: A61K31/70
- IPC: A61K31/70 ; C07H19/073
Abstract:
The present invention relates to the gemcitabine prodrug 1-(2,2-difluoro-2-deoxy-β-D -ribofuranosyl)-4-(2-propyl-1-oxopentyl)aminopyrimidin-2-one useful as an oral drug for the treatment of cancer.
Public/Granted literature
- US20090156547A1 AMIDE PRODRUG OF GEMCITABINE, COMPOSITIONS AND USE THEREOF Public/Granted day:2009-06-18
Information query
